---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-111750"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2023-10-26T23:59:59+00:00"
generated_at: "2026-06-09T08:02:05.197601+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CVRx Q3 revenue up 70% to $10.5M, raises FY2023 revenue guidance

## Summary
- Revenue $10.5M (+70% YoY); U.S. HF revenue $9.4M (+92% YoY).
- Net loss $9.0M ($0.43/sh) vs $9.8M ($0.48/sh) in Q3 2022; cash burn improved to $8.2M from $13.0M in Q2.
- Active implanting centers 159 (+75% YoY); sales territories grew to 35.
- FY2023 revenue guidance raised to $38.5M-$39.0M (from $37.0M-$38.5M); Q4 revenue expected $10.5M-$11.0M.
- CMS advisory panel unanimously recommended higher Barostim payment code; final rule expected late Nov.

## SEC filing metadata
- accession: 0001104659-23-111750
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2023-10-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465923111750/0001104659-23-111750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465923111750/tm2329194d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-111750
- JSON: https://secwatch.observer/filing/0001104659-23-111750.json
- Plain text: https://secwatch.observer/filing/0001104659-23-111750.txt

## Key facts
- Earnings Releases
  CVRx, Inc. reported the third quarter of 2023 results: revenue $10.5 million, net income $9.0 million, EPS $0.43 per share.
  - Period: the third quarter of 2023
  - Revenue: $10.5 million
  - Net income: $9.0 million
  - EPS: $0.43 per share
  - Result: reported results
  source text: cardiovascular diseases, today announced its financial and operating results for the third quarter of 2023. Recent Highlights · Total revenue for the third quarter of 2023 was $10.5 million, an increase of 70% over the prior year quarter · U.S. Heart Failure (HF) revenue for the third quarter of 2023 was $9.4 million, an increase of 92% over the prior year quarter ·
  evidence_url: https://www.sec.gov/Archives/edgar/data/1235912/000110465923111750/0001104659-23-111750-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.